Story Highlight
– Sufferers face debilitating symptoms during hay fever season.
– NHS discontinued hay fever jabs due to safety concerns.
– Allergen immunotherapy could offer effective long-term relief.
– Limited awareness and access to allergy treatments in UK.
– Costs for private immunotherapy can be prohibitively high.
Full Story
As the arrival of warmer months ushers in the proliferation of pollen, those affected by severe allergies face increasingly daunting challenges. The condition known as hay fever, or allergic rhinitis, can impair daily life significantly, making simple activities feel monumental. Individuals grappling with this affliction often resort to numerous measures to alleviate their discomfort, yet relief remains elusive for many.
For sufferers, the onset of hay fever typically begins in spring, when tree pollen levels surge. This year, reports indicate that the pollen season commenced as early as February, with tree pollen levels categorised as “very high.” Consequently, experts are warning that this could herald a particularly intense pollen season, prompting allergists to advise individuals to stock up on antihistamine medications as an early precaution.
Despite dependence on over-the-counter remedies like antihistamines, many find that these treatments fail to provide adequate relief. The situation has prompted a growing number of people to explore alternate treatments, including an injection known as Kenalog (triamcinolone acetonide), which was previously offered by the National Health Service (NHS) until its discontinuation in 2018. Concerns about safety and a lack of conclusive evidence regarding its long-term effectiveness led to its withdrawal from NHS protocols.
Dr Leyla Hannbeck, CEO of the Independent Pharmacy Association, explains the rationale behind the cessation of the Kenalog injection. “It can weaken your immune system and that opens you up to infections which can have long-term implications,” she states. “It’s not licensed in the UK as a treatment for hay fever anymore, and clinics offering it as an alternative should avoid doing so.” Nonetheless, a study conducted by the National Pharmacy Association revealed that a significant proportion of pharmacies—45 per cent—reported receiving inquiries from patients regarding the availability of this injection as an allergy therapy last spring.
Despite the known risks associated with steroids, such as potential bone density loss and other serious side effects, some individuals turn to private clinics or even beauty salons to receive the Kenalog injection—a move that can cost between £75 and £90. The desperation for relief often blinds patients to the inherent dangers of such treatments. One hay fever sufferer, Nancy, shared her experience after undergoing the injection: “My life has been changed already. Within 48 hours, there’s already a noticeable difference.”
However, allergist Professor Adam Fox cautions against assuming that the injection is a safe or effective remedy for all. He compares the use of Kenalog for joint conditions to its application for hay fever, elucidating the potential consequences of systemic steroid administration. “With hay fever, you’re injecting it into your bum, which gets a wider circulation,” he explains, emphasising risks related to bone health. “The worry is that if you’re overweight, have a history of osteoporosis, or smoke, this combination with an added dose of steroids could be detrimental.”
Fortunately, there is another path available for those affected by hay fever: allergen immunotherapy (AIT), often referred to as pollen desensitisation. This method involves administering regular small doses of pollen allergens to gradually recalibrate the immune response over a period of three years. Clinical trials indicate that AIT can significantly enhance quality of life for allergy sufferers, with improvement rates averaging 30 per cent in the first year, climbing to 70 per cent by the third year. Unfortunately, many people, including healthcare practitioners, remain largely uninformed about this treatment.
Professor Fox lamented the lack of awareness among medical professionals, noting that allergy training is not heavily emphasised in medical education. “The likelihood that your doctor will even know that there’s something that goes above and beyond nasal sprays and antihistamines is low,” he remarked. Consequently, many patients find themselves under-informed about their treatment options.
Timing is critical when considering allergy immunotherapy. For tree pollen, treatment ideally starts in October, while for grass pollen, individuals need to begin by the end of January to achieve maximum benefits. While AIT is not a panacea and may still require accompanying antihistamine use, it has the potential to make living with allergies far more manageable.
Recent announcements from the National Institute of Clinical and Healthcare Excellence have sparked hope that accessibility to AIT might improve. Recommendations have been made for the NHS to prescribe a tree pollen tablet, Itulazax, and considerations for grass pollen tablets are ongoing. Professor Fox commented, “We hope that because of that recommendation, access to these treatments gets better, but there are significant barriers that still need addressing.”
Limited access to specialist allergy services in the UK is another hurdle. Those seeking treatment often find themselves competing for appointments with individuals who have more severe allergic reactions, which results in lengthy waiting times and delays in care. For instance, comparison with other European nations reveals a stark contrast; while UK patients are significantly underrepresented in allergen desensitisation programmes, many in countries like Germany benefit from more comprehensive options.
Those who opt for private treatment often face substantial financial burdens. The same sublingual immunotherapy tablet recommended by the NHS can incur costs of around £130 per month, culminating in an estimated total of £4,200 over three years.
As the pollen season looms, upcoming discussions on the National Allergy Strategy will present recommendations to the UK government aimed at enhancing allergy management. The overarching aim remains to improve patient access to effective treatments. Reflecting on the available options, individuals suffering from hay fever must not only contend with the physical toll of the condition but also navigate a complex healthcare landscape. For many, the question remains: what is the best course of action in managing debilitating allergy symptoms while ensuring their health is not jeopardised?
Our Thoughts
This article highlights several health and safety concerns regarding the management of allergies in the UK. One of the primary issues is the lack of awareness regarding allergen immunotherapy (AIT) among healthcare practitioners. Training related to allergies should be enhanced within medical education to ensure practitioners can guide patients towards effective treatments, aligning with the Health and Safety at Work Act 1974, which requires adequate employee training and safe practices.
Furthermore, the absence of available allergen treatments and reliance on risky alternatives like Kenalog injections breach the Medicines Act 1968, which regulates the safety and efficacy of medical treatments. Patients are lured to private clinics despite safety concerns, indicating a significant gap in NHS guidance and access to safe options.
To prevent similar incidents, increasing public awareness about available allergen treatments, improving access to specialist clinics, and enhancing the training of healthcare providers on allergy management are essential. Establishing stronger regulatory oversight for private offerings could prevent patients from seeking unsafe alternatives due to inadequate information from health services. Overall, a coordinated national strategy for allergy management is crucial to safeguard public health.
